Catalyst Wire Dossier Catalyst Wire Dossier

Fenebrutinib

Fenebrutinib · Hoffmann-La Roche
Drug timelines are a Plus or Pro feature.

6 regulatory and trial events tracked for Fenebrutinib, covering 2020-09-25 to 2026-04-13. Get the full timeline:

Most recent: Clinical Trial Update: A Pharmacokinetics (PK), Pharmacodynamics (PD), Safety and Tolerability Study of Fenebrutinib in Children and Adolescents With Relapsing Multiple Sclerosis (RMS) [Phase 2]

See pricing